At a glance
ClinicalIndex Comparison RecordN/ACompleted· 434 enrolled
Drug / intervention
Pemetrexeddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line With Pemetrexed - An Observational Study
In Brief
An observational study evaluating Pemetrexed for Lung Neoplasms. Completed, enrolled 434 participants across 38 sites in 2 countries.
Detailed Summary
This large, non-randomized observational study is being conducted to provide data about the impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of non-small cell lung cancer (NSCLC) in a routine medical care setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLung Neoplasms
CountriesPuerto Rico, United States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedJul 2007
Primary CompletionMar 2011
TodayJul 2026
First PostedJul 9, 2007
Enrollment StartFeb 1, 2007
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 19.0 years ago
Interventions
Pemetrexeddrug
Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient